45 results about "Plasma levels" patented technology

Described herein are dosage forms of enantiomerically enriched (S)-bupropion or enantiomerically enriched (R)-bupropion. The (S)-bupropion or the (R)-bupropion may be deuterium enriched, or may have natural isotopic abundance. These dosage forms may be administered, either fed or fasted, to treat a condition recited herein, to achieve a certain pharmacokinetic parameter of a bupropion or a metabolite of a bupropion, and / or to enhance dextromethorphan plasma levels.

Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.

This invention relates to methods of lowering plasma levels of endothelial lipase (EL) in patients in need thereof comprising administering MEDI5884 to subjects at a dose of from about 50 mg to about 600 mg per month.

Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.

This document provides methods and materials involved in assessing mammals with acute decompensated heart failure (ADHF), as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of plasma CNP and the level of urinary CNP to determine whether or not a mammal is developing or likely to develop more severe ADHF, as well as methods and materials for using the level of plasma CNP and the level of urinary CNP to identify patients having an increased likelihood of experiencing a poor outcome are provided.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for excreting dampness and strengthening heart as well as a preparation method and application thereof. The active ingredient of the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 3-10 parts of prepared radix aconiti carmichaeli, 5-15 parts of rhizoma zingiberis, 5-15 parts of honey-fried licorice root, 10-30 parts of radix pseudostellariae, 5-15 parts of wine-processed radix cyathulae, 10-30 parts of radix salviae miltiorrhizae, 3-10 parts of pericarpium citri reticulatae, 10-30 parts of rhizoma alismatis and 5-15 parts of radix platycodonis. The traditional Chinese medicine has the effects of tonifying deficiency, dispelling excess, tonifying qi, nourishing yin, excreting dampness and promoting blood circulation, treating root causes by tonifying qi and nourishing yin and treating symptoms by excreting dampness and promoting blood circulation, and achieving the effect of treating both symptoms and root causes. Clinical research shows that the traditional Chinese medicine composition not only can reduce the plasma NT-proBNP level of a patient with ejection fraction retention type heart failure, but also can improve the score of the patient in the Life Quality Scale of Clinical Myocardiopathy Patient, and can be used for treating related diseases such as ejection fraction retention type heart failure and the like.

The present disclosure provides methods and materials related to MANPs. In one embodiment, the present disclosure provides a method for treating hypertension with metabolic syndrome by administering MANPs to a patient in need of such treatment. In one embodiment, the present disclosure provides a method comprising administering MANPs to a patient to lower blood pressure (BP). In one embodiment, the method of the present disclosure is employed to treat patients with low baseline cGMP levels. In one embodiment, the present disclosure provides a therapeutic method using MANPs to increase or improve plasma cGMP levels, plasma ANP-like peptide levels, insulin sensitivity, or plasma NEFA levels. In one embodiment, the present disclosure provides a therapeutic method using MANPs to lower plasma glucose levels.

This disclosure provides compounds of formula: and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds, and their use in the treatment of cardiovascular disease and elevated Lp(a) plasma levels. [Formula 1] TIFF2026525345000055.tif58128

A preparation method for a novel compound which reduces blood plasma Lp(a) levels, and an intermediate compound of the novel compound. The novel compound is biochemically effective and physiologically active.

The invention discloses application of a gene editing virus interfering expression and secretion of enzyme prototype cathepsin D in brain trauma, belongs to the field of gene functions and application, and finds that brain injury is aggravated and nerve dysfunction is aggravated due to the fact that the level of the enzyme prototype cathepsin D in plasma is increased due to the brain trauma through detection. The mechanism is as follows: the enzyme prototype cathepsin D enhances the transendocytosis effect of cerebral vascular endothelial cells after brain trauma, so that plasma inflammatory factors are gathered in damaged brain tissues; meanwhile, the expression of cerebrovascular endothelial cells VCAM-1 is also up-regulated, and neutrophil infiltration in an injured brain region after brain trauma is intensified. Research finds that down-regulation of plasma enzyme prototype cathepsin D can alleviate inflammatory factor concentration and neutrophil density in a brain injury area after trauma, and alleviate neurological function impairment of mice. Aiming at the functions of the plasma prototype cathepsin D, a strategy for reducing the plasma level of the plasma prototype cathepsin D by a gene editing technology for interfering the prototype cathepsin D is provided for treating the cerebral trauma.

To provide a method for treatment of patients suffering from a hyperinflammatory syndrome without hampering the inflammatory response of the patients or at least to a much lesser extent.SOLUTION: Provided is an antagonist of a mammalian P2X7 receptor (P2X7R) for use in the treatment of a hyperinflammatory syndrome in a mammalian patient, by primary lymph node targeted administration of the P2X7R antagonist in the patient to a concentration of the antagonist of the mammalian P2X7R in the targeted lymph nodes that is above the maximal tolerable plasma level of the antagonist in the mammal.SELECTED DRAWING: None

The invention discloses application of turmeric volatile oil in preparation of a medicine for preventing and treating acute lung injury. The turmeric volatile oil is extracted and prepared by adopting a steam distillation method, the turmeric volatile oil is subjected to characterization analysis in combination with UPLC (Ultra Performance Liquid Chromatography), and the influence of the turmeric volatile oil on rat lung indexes, lung tissue pathological changes and plasma IL-1beta, TNF-alpha and IL-6 levels is analyzed through LPS (Lipopolysaccharide)-induced replication of a rat acute lung injury model. The turmeric volatile oil is proved to have a remarkable technical effect in treating the acute lung injury. The invention provides new application of turmeric volatile oil in acute lung injury treatment, and provides a new natural medicine source for acute lung injury prevention and treatment.

Microvascular leak plays a critical role in the outcome of sepsis. Counteracting vascular leakage has recently raised a huge interest in the field but therapeutic targets and translation studies are crucially lacking. The inventors hypothesized that ANGPTL4 might counteract lipopolysaccharide-induced vascular hyperpermeability. Mechanistically, the inventors show that the C-terminal fragment of ANGPTL4 recapitulates full-length ANGPTL4 inhibition of vascular permeability by stabilizing endothelial cell adherent junctions whereas the N-terminus has no such effect. The inventors further demonstrate that giving human recombinant c- ANGPTL4 to mice prevents microvascular leak and mortality induced by LPS. In humans, the inventors describe the association between ANGPTL4 plasma level at time of inclusion and 90- day mortality in sepsis or septic shock patients French and European Outcome Registry in Intensive Care Units (FROG-ICU). In conclusion, the inventors demonstrate that suppressing vascular permeability by c-ANGPTL4 could be a novel therapeutic for the treatment of sepsis capillary leak syndrome. Either alone or in combination with existing drugs, c-ANGPTL4 could contribute to the reduction of mortality in patients with shock states.

A method of reducing elevated plasma levels of cholesterol in a subject is disclosed. Also disclosed is a method of treating hypercholesterolemia in a subject. The method comprises administering to the subject an effective amount of Compound 1, or a pharmaceutically acceptable salt thereof, in the absence of a cholesterol-lowering drug.

Dosage forms of enantiomerically enriched (S)-bupropion or enantiomerically enriched (R)-bupropion are described herein. The (S)-bupropion or the (R)-bupropion may be rich in deuterium, or may have a natural isotope abundance. These dosage forms may be administered upon eating or fasting to treat conditions described herein, to achieve certain pharmacokinetic parameters of bupropion or bupropion metabolites, and / or to increase dextromethorphan plasma levels.

The present invention relates to a CXCR4 inhibitor compound for use in the treatment of a severe acute respiratory distress syndrome (sARDS), wherein the sARDS is characterized by a dysregulation of NETosis which may be measured by the plasmatic levels of cDNA, citrullinated histone H3, neutrophil elastase, interleukin-8, myeloperoxidase-DNA complexes and / or calprotectin. The present invention also relates to a method of prognostic of severe ARDS, a pharmaceutical composition for use in the treatment of severe acute respiratory distress syndrome (ARDS), a kit of prognostic of severe ARDS in a subject and the use of NETosis biomarkers.

The present disclosure provides compounds of the formula: and pharmaceutically acceptable salts thereof, and compounds of the formula: and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds, and their use in the treatment of cardiovascular disease and elevated Lp (a) plasma levels.

The present disclosure provides a method of treating or inducing cognitive preservation in a patient with Alzheimer's disease, comprising administering an effective amount of CT1812. The effective amount of CT1812 is 100 mg or 300 mg administered orally once daily. The method demonstrates improvements in cognitive outcomes compared to placebo across multiple measures including ADAS-Cog11, MMSE, ADCS-ADL, and ADCS-CGIC. The method demonstrates improvements in cognitive outcomes in patients with low plasma levels of phosphorylated tau 217 prior to administration.

The present application relates to the use of GSDMD in the diagnosis and therapeutic effect evaluation of diseases related to chest pain. Quantitative analysis of the GSDMD levels in serum / plasma can provide an objective basis for the early diagnosis of diseases related to chest pain, and help formulate a rational regimen for the treatment of diseases related to chest pain.

The present disclosure provides compounds of the formula: and pharmaceutically acceptable salts thereof, and compounds of the formula: and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds, and their use in the treatment of cardiovascular disease and elevated Lp (a) plasma levels.

This invention provides the application of neuregulin protein in the manufacture of drugs for preventing, treating, or delaying human heart failure, and methods for using such drugs. [Solution] The method includes: first examining the patient before treatment, wherein the examination includes detecting plasma levels of NT-proBNP or BNP; and subsequently providing appropriate treatment based on the examination results. If the examination results are within the optimal therapeutic range, the patient is suitable for treatment of heart failure by administering an effective dose of Neureglin.

This invention relates to the application of chebulic tannic acid in the preparation of drugs for treating atherosclerosis, belonging to the field of atherosclerosis treatment technology. This invention discovers that chebulic tannic acid can specifically bind to the catalytic pocket region of SAHH protein, significantly enhancing its efficiency in hydrolyzing SAH, in ApoE... ‑ / ‑ In a mouse model, chebulic tannic acid significantly reduced plasma SAH levels. Simultaneously, the aortic plaque area decreased in mice treated with chebulic tannic acid. This demonstrates that chebulic tannic acid has a therapeutic effect on atherosclerosis. This invention, by regulating methionine cycle homeostasis through chebulic tannic acid, not only reduces plasma SAH and tHcy levels but also effectively inhibits inflammatory responses and oxidative stress, significantly improving atherosclerosis.

The invention discloses a substituted pyridine propionic acid derivative and application thereof, and belongs to the field of chemical medicines. According to the pyridine propionic acid compound shown in the general formula (I) or the pharmaceutically acceptable salt of the pyridine propionic acid compound, in the compound, an A ring, a B ring and a C ring are independently selected from X1, X2, X3 and X4 are independently selected from N and CR, and at least one of X1, X2, X3 and X4 in the A ring is N. The compound disclosed by the invention has an excellent Lp (a) inhibiting effect and can be used as a medicine for reducing the Lp (a) level of plasma.

The present invention relates to a compound of formula (I), a pharmaceutically acceptable salt, stereoisomer or isotopically labeled substance thereof, a pharmaceutical composition thereof, and the use thereof in the preparation of a drug for treating a disease associated with elevated plasma Lp(a) levels.

This invention relates to a 24 hour extended release dosage composition and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet compositions which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release composition of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.

Bupropion for use in a method for increasing plasma levels of dextromethorphan in a human subject who is an extensive metabolizer of dextromethorphan and in need of dextromethorphan treatment, wherein the use comprises daily co-administration of bupropion with dextromethorphan to the human subject for at least eight consecutive days and wherein, on the eighth day of co-administration of bupropion with dextromethorphan, the AUC0-12 of dextromethorphan is at least 400 ng·h / ml. The application contains 14 additional claims.

A method for providing a prediction as to whether a subject with a cancer exhibits a beneficial response to arginine deprivation therapy including determining the plasma level of arginine in the subject, followed by administering to the subject an arginine deprivation therapy alone or in combination with an anti-cancer agent based on the determined plasma level of arginine. According to some embodiments of the present disclosure, the anti-cancer agent is selected from the group consisting of FOLFOX, docetaxel, cisplatin, pemetrexed, pembrolizumab, and a combination thereof.

The present disclosure provides compounds of formula: and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds, and their use in the treatment of cardiovascular disease and elevated Lp (a) plasma levels.

The invention discloses a MAFLD related biomolecular marker and application, the biomarker is human interleukin-24, and the amino acid sequence of the biomarker is as shown in SEQ ID No.1. The invention reveals that the expression level of human interleukin-24 (IL-24) in the plasma of a patient with the metabolism-related fatty liver disease (MAFLD) is obviously different from that of healthy people for the first time, and large-scale clinical sample verification proves that the plasma IL-24 level of the patient with the MAFLD is obviously reduced. The discovery provides a new molecular marker for clinical diagnosis of MAFLD.

A computer implemented method for determining a dosage of dabigatran for administering to a patient, the method comprising: receiving patient data relating to a patient, wherein the patient data includes a kidney function metric; processing the patient data with a dosage calculator to determine the dosage of dabigatran for administering to the patient, wherein the dosage calculator is derived from a plasma level prediction model; and indicating the dosage.